- $202.26m
- $49.80m
- 40
- 31
- 48
- 34
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.36 | ||
| Price to Tang. Book | 1.36 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -33.78% | ||
| Return on Equity | -25.74% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | 13.05 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, CTX-009, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor and its ligand PD-L1, two validated immune-oncology targets.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- March 20th, 2018
- Public Since
- November 13th, 2020
- No. of Shareholders
- 100
- No. of Employees
- 32
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 137,589,171
- Address
- 80 Guest Street, BOSTON, 02135
- Web
- https://www.compasstherapeutics.com/
- Phone
- +1 6175008099
- Auditors
- CohnReznick LLP
Upcoming Events for CMPX
Similar to CMPX
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
As of Today at 19:05 UTC, shares in Compass Therapeutics. are trading at $1.47. This share price information is delayed by 15 minutes.
Shares in Compass Therapeutics. last closed at $1.47 and the price had moved by -47.12% over the past 365 days. In terms of relative price strength the Compass Therapeutics. share price has underperformed the S&P500 Index by -56% over the past year.
The overall consensus recommendation for Compass Therapeutics. is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Compass Therapeutics. does not currently pay a dividend.
Compass Therapeutics. does not currently pay a dividend.
Compass Therapeutics. does not currently pay a dividend.
To buy shares in Compass Therapeutics. you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.47, shares in Compass Therapeutics. had a market capitalisation of $202.26m.
Here are the trading details for Compass Therapeutics.:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: CMPX
Based on an overall assessment of its quality, value and momentum Compass Therapeutics. is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Compass Therapeutics. is $9.17. That is 523.81% above the last closing price of $1.47.
Analysts covering Compass Therapeutics. currently have a consensus Earnings Per Share (EPS) forecast of -$0.48 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Compass Therapeutics.. Over the past six months, its share price has underperformed the S&P500 Index by -36.97%.
As of the last closing price of $1.47, shares in Compass Therapeutics. were trading -24.34% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Compass Therapeutics. PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.47.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Compass Therapeutics.'s directors